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Abstract
Implanted defibrillators have become mainstream therapy for the prevention of sudden cardiac 
death from ventricular tachyarrhythmias.  A decade of studies has confirmed the superiority of 
ICDs over antiarrhythmic drug therapy in prolonging the life of patients with a prior history of 
sustained VT or VF. More recent studies have compared ICD therapy to drugs or no 
antiarrhythmic therapy as 'primary prophylaxis' in patients considered at high risk for sudden 
death or with prior MIs.   In selected patients, ICDs lead to important relative and absolute 
reductions in mortality in patients with no prior history of sustained VT or VF.  Clinicians need 
to carefully consider these studies in their management of patients with CAD and severe LV 
dysfunction.
Introduction 
.     The understanding that cardiac death and, in particular, sudden cardiac death from fatal 
ventricular arrhythmias, is one of the most common causes of death in Western society is now 
widespread.   Following   the   spectacular   successes   of   thrombolytic,   antiischemic,   and 
revascularization therapies in the 1990's, focus has increasingly turned to the care of patients 
with the chronic consequences of coronary artery disease, chiefly left ventricular dysfunction 
and heart failure, and the propensity to sudden arrhythmic death. India being at present a nation 
facing an epidemic of coronary artery disease; would consequently have more & more of its 
populace in chronic CAD with risk of SCD.                                                                  . 
.    Although it has been very clearly established that patients with left ventricular dysfunction, 
with or without symptomatic heart failure, are at high risk for out-of-hospital cardiac arrest, and 
undocumented but presumably arrhythmic sudden death, preventing such deaths has posed a 
major therapeutic challenge.  First, it is difficult if not impossible to predict, with any reasonable 
degree of certainty, which particular patients are destined to suffer fatal arrhythmias, and which 
others are destined to remain clinically stable, or at least be free of serious ventricular 
arrhythmias.  If one could identify such patients, then therapy could, of course, be targeted to 
only that select proportion whose destiny it is to suffer VT or VF (this represents approximately 
40-60% of all patients with moderate to severe left ventricular dysfunction).1  Tests to identify 
patients at particularly high risk of sudden death have included the ability to induce ventricular 
tachycardia  or   fibrillation   at   invasive   electrophysiologic   study;   the   documentation   of 
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nonsustained ventricular tachycardia on holter or in-hospital ECG monitoring; the presence of 
subtle (not visible to the naked eye) ECG abnormalities of depolarization and repolarization 
using the filtered, signal-averaged ECG, or the presence of microvolt T-wave alternans; and the 
presence  of abnormal autonomic modulation of  cardiac  function,  by the  registration  of 
abnormally low heart rate variability (HRV), or depressed baroreceptor sensitivity.                    . 
.    Although each of these tests is of some prognostic value, they are insufficiently accurate, for 
practical clinical purposes, to direct therapy. Even amongst patients with poor ejection fraction, 
past history of myocardial infarction & the presence of ventricular scar are actually believed to 
be at high risk of sudden cardiac death. However there is no available diagnostic modality by 
which one can identify the exact population of patient liable to have SCD amongst thousands 
with these characteristics. This is tragic but true that this is in fact a serious limitation in our 
capability to triage patients requiring protection from SCD, as the incidence of sudden death 
amongst all patients with prior myocardial infarction is relatively low.                                         . 
.       A second conceptual and practical problem is our inability to identify the timing, or 
proximate causes of sudden death from VT/VF.  Such events appear to occur "out of the blue", 
and there are no clearly identifiable factors, which precede sudden cardiac death in most 
individuals.  Although coronary artery disease is the most important etiologic factor leading to 
life threatening ventricular arrhythmias, angina, other manifestations of myocardial ischemia, 
sudden worsening of heart failure, or behavioural factors such as stress or exercise are rarely 
observed to immediately precede sudden death.                                                                             . 
.    Improved acute and long term therapies have increased survival for patients with myocardial 
infarction, leading to a relative increase in the number of the patients with chronic coronary 
disease and left ventricular dysfunction, who are nevertheless stable and not expected to suffer 
imminent recurrent infarction or progressive heart failure. Such patients usually feel relatively 
well, and may require some persuasion to consider prophylactic therapy for cardiac arrhythmias, 
which from a subjective standpoint, can only decrease their quality of life in the short term.  In 
confronting these dilemmas, clinicians through the 1980's and 1990's were optimistic that 
sudden death could be prevented by the administration of antiarrhythmic drug therapy.  This 
approach had the conceptual benefit of being able to be delivered to a large group of patients at 
relatively low risk, as a "chemoprophylaxis" of sudden cardiac death.   With the spectacular 
failure of class I drugs, for example with Flecainide following myocardial infarction, attention 
has turned to drugs that prolong cardiac repolarization (class III drugs).  The most extensively 
studied of these drugs is amiodarone.  Several very large trials have examined in detail the 
potential usefulness of amiodarone in preventing sudden death in high risk patients with 
coronary artery disease and left ventricular dysfunction, the largest being the EMIAT study 
(European Myocardial Infarction Arrhythmia Trial),2  and the CHF-STAT study (Congestive 
Heart Failure - Survival Trial of Antiarrhythmic Therapy).3  The CAMIAT study (Canadian 
Amiodarone   Myocardial   Infarction   Arrhythmia   Trial)4  also   included   patients   with   prior 
myocardial infarction, most of whom had at least moderate left ventricular dysfunction, as well 
as frequent ventricular premature beats.   All of these studies were randomized placebo-
controlled clinical trials.   None were able to show neither a statistically significant, nor a 
clinically meaningful reduction in all cause cardiac mortality.   Although meta analyses of 
amiodarone have suggested a small, and statistically significant reduction in all cause mortality 
in high risk populations, individual trials in patients with coronary artery disease and left 
ventricular dysfunction leaves us scant hope that amiodarone will be highly useful in this 
population of patients. The progressively increasing burden of adverse effects from amiodarone 
is another barrier to its use.  Given the paucity of evidence, there is no good reason to prescribe 
amiodarone as primary prophylaxis for ventricular tachycardia or fibrillation in patients with 
coronary  artery disease and  left ventricular dysfunction,  but no  symptoms  of sustained 
ventricular arrhythmias.  
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Large studies have also examined the potential benefit from new class III antiarrhythmic drugs 
in the prevention of sudden death following MI or with heart failure, including studies of 
dofetilide (DIAMOND5 and DIAMOND-CHF6), and azimilide (the ALIVE study7). These also 
failed to show any difference between drug and placebo treated patients in sudden or all cause 
mortality.  It is extremely important to note that beta-blocker therapy is of undoubted benefit in 
prolonging life in patients following myocardial infarction, particularly those with heart failure 
or extensive left ventricular dysfunction.  Beyond the universal requirement for beta blockers 
unless   absolutely   contraindicated,   there   is   however   not   much   room   for   optimism   that 
antiarrhythmic drugs, at least for the time being, will be even a partial solution to the problem of 
sudden cardiac death in susceptible coronary populations.
The Implanted Defibrillator                                                                                           . 
.     The implanted defibrillator represents an effective, if intellectually inelegant therapy to 
prevent death from ventricular arrhythmias.   The device, after all, does not prevent such 
arrhythmias but only treats them after they occur.   Shocks are painful and unpleasant, the 
devices are expensive, a surgical procedure is required for its implantation, and the follow-up of 
patients can be technically challenging.   Where do we stand with respect to the evidence 
concerning implanted defibrillators and sudden death?                                                     . 
.     There is extensive information regarding the efficacy of implanted defibrillator therapy.  
Appropriately tested devices have a 99% or greater probability of successfully restoring a 
perfusing rhythm in patients with ventricular tachycardia or ventricular fibrillation.   Current 
devices can be implanted with a less than 1% major morbidity or mortality, with a surgical 
complexity and morbidity very similar to that of pacemaker implantation.                                    . 
.    Studies in patients with a prior history of cardiac arrest, or sustained ventricular tachycardia; 
what is called the secondary prevention, have demonstrated convincingly that the implanted 
defibrillator is both effective, and superior to antiarrhythmic drug therapy in preventing all cause 
mortality in such patients. The AVID,8 CIDS,9 and CASH10 studies, and their meta-analysis,11 
have shown an approximately 20-30% reduction in all cause mortality in such patients.  The 
greatest relative benefit from defibrillators over antiarrhythmic therapy (primarily amiodarone) 
occurs in those with the worst left ventricular function, and the elderly.12  Since the majority of 
sudden deaths occur in patients without a prior history of documented sustained ventricular 
tachycardia or ventricular fibrillation, studies have assessed the usefulness of defibrillators as 
"primary prophylaxis" of sudden cardiac death.  The accumulated evidence from these studies is 
briefly reviewed below.
Clinical   Trials                                                                                    . 
.    Initial trials focused on the selection of patients expected to be at particularly high risk of 
sudden cardiac death, based on a combination of low ejection fraction, and an additional risk 
marker for sudden cardiac death.                                                                                                    . 
.     The MADIT I study assessed patients with coronary artery disease, poor left ventricular 
function, and asymptomatic nonsustained ventricular tachycardia, with inducible VT or VF at 
electrophysiologic study, not suppressible by antiarrhythmic drug therapy.13  This study, the 
first to document a potential benefit from prophylactic ICDs, showed a 54% reduction in 
mortality in patients implanted with a defibrillator as opposed to those receiving “conventional 
medical therapy”.  The weaknesses of this trial included its relatively small size, inadequate 
therapy with beta blockers and ACE inhibitors, and the clinically impractical sequence of EP 
study and need for VT induction, followed by attempted VT/VF suppression with procainamide, 
that was required for risk stratification.  Nevertheless, the results from this study led to FDA 
approval of implanted defibrillators for the particular subset of patients meeting the inclusion 
criteria for this study.
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             The CABG PATCH study randomized patients immediately following successful 
aortocoronary bypass surgery, if they met the inclusion criteria of a low ejection fraction 
(<35%), and a positive signal-averaged ECG, to either an implanted defibrillator or control 
therapy without the ICD.14   All devices were attached to the heart by means of epicardial 
defibrillator   patches   (which   are   no   longer   used   during   the   CABG   procedure. 
            This study failed to show any benefit whatsoever from the implanted defibrillator, but 
both defibrillator and no defibrillator patients had a low cardiac mortality (5.9% per year), 
suggesting that surgical revascularization has a very important protective effect against sudden 
death. 
            The MUSTT study, like the MADIT study, also selected patients with coronary artery 
disease and ejection fraction of <40% if they had asymptomatic nonsustained VT on holter or in-
hospital ECG monitoring, as well as inducible VT at EP study.15 They were randomized to 
either   "electrophysiologically   guided",   or   no   antiarrhythmic   drug   therapy.   The 
electrophysiologically guided arm could include antiarrhythmic drugs designed to suppress the 
inducibility   of   ventricular   tachycardia,   those   that   would   render   inducible   arrhythmias 
hemodynamically stable, or an implanted defibrillator.  The choice between defibrillator versus 
drug therapy was not randomized.                                                                                             
             Freedom   at   5   years   from   sudden   death   was   significantly   lower   in   the 
electrophysiologically guided arm (25 vs. 32%, p=0.04) but all cause mortality was not (48 vs. 
42%, p=0.06).   However, a secondary analysis comparing patients with no antiarrhythmic 
therapy, the implanted defibrillator, and antiarrhythmic drug therapy, showed some striking 
trends.   The relative risk of death from all causes in the ICD group compared to the no 
antiarrhythmic   therapy   group   was   0.45   (95%,   CI   0.32-0.63)   and   compared   to 
electrophysiologically guided antiarrhythmic drug therapy was 0.40 (0.27-0.59).  Although this 
is not strictly a randomized therapy assignment outcome, the study was widely and reasonably 
interpreted as showing superiority of the implanted defibrillator to no antiarrhythmic therapy or 
antiarrhythmic drug therapy.  The observation that the "electrophysiologically guided" strategy 
was increasingly superior over no antiarrhythmic therapy as ICDs were increasingly frequently 
used over time, and relatively better in those centers that used ICDs more frequently, lent 
plausibility to the belief that it was the defibrillator which contributed all of the observed benefit 
of the antiarrhythmic therapy arm.                                                                                                 
            As a consequence of the MUSTT study, most expert bodies, stipulating guidelines for the 
treatment of ventricular arrhythmias, concluded that patients with coronary artery disease, 
ejection fraction <40%, and nonsustained VT, if they had inducible ventricular tachycardia at EP 
study, should preferably be treated with an implanted defibrillator.16                                     
            Up until very recently, the database above was sufficiently ambiguous and related to a 
sufficiently  select  subgroup   of   patients  (those  with  all  of   CAD,   low   ejection  fraction, 
nonsustained VT, and inducible VT/VF at EP studies), that these recommendations have not 
been widely adopted in everyday clinical practice.                                                                        
            The MADIT II study, published in March 2002,17 took a simplified approach to the 
testing of the hypothesis that implanted defibrillators would reduce all cause mortality in at risk 
populations.  The only criteria to identify patients at risk from sudden death were the presence of 
coronary artery disease, a prior myocardial infarct, and an ejection fraction of <30%.  This study 
randomized a total of 1232 patients to either the ICD (742 patients), or conventional medical 
therapy (490 patients, a 3:2 ratio).  Neither nonsustained VT nor an electrophysiologic study was 
required for entry into this study.                                                                                           
             The patient population in this study was reasonably representative of a potentially very 
large group of patients with chronic coronary artery disease and prior MI.  The mean age was 65 
years, and 70% of patients were either NYHA class II or I.  A majority had a remote history of 
coronary bypass surgery (57%), or coronary angioplasty (44%).  In the vast majority, more than 
6 months had elapsed since their most recent MI. Interestingly enough the associated drug 
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therapy   that   most   patients   in   the   trial   had   was   sufficiently   appropriate   as   to   allow 
generalizability in this trial. Seventy percent were receiving ACE inhibitors, 70% beta-blockers, 
and 57% digitalis.  Sixty-six percent received statins.  About 12% were receiving amiodarone at 
last contact (presumably most often for atrial fibrillation), and only 9% received calcium 
channel blockers and 3% received class I antiarrhythmic drugs.                                        
             Patients were followed to a common primary endpoint of death from any cause.  The 
pre-specified mortality efficacy boundary was achieved just over 4 years after the study began, 
after an average follow-up of 20 months.                                                                           
             The defibrillator therapy resulted in an increasing mortality benefit over conventional 
therapy over time, with an aggregate 31% reduction in the risk of death at any time interval, 
including a relative decrease of mortality of 12%, 28%, and 28% at 1, 2, and 3 years 
respectively.  In absolute terms, this meant a 1%, 6%, and 9% reduction in mortality at 1, 2, and 
3 years; in other words, the number needed to treat (NNT) to prevent 1 death by 3 years was 
approximately 11.   This NNT compares very favorably to other cardiovascular therapies in 
common use, for example beta-blockers (CIBIS 2, NNT = 23), statins (4S, NNT = 28), or ACE 
inhibitors (SAVE, NNT = 20).  There was a slightly higher probability of hospitalization for 
heart failure in the ICD group (11 per 1000 months), versus the control group (9 per 1000 
months, p=0.09).                                                                                                                             
             Subsequent further subgroup analysis showed that patients with QRS prolongation of 
>120  msec  at   baseline  received  a   particularly  and  dramatically  large   benefit  from  the 
implantation of an ICD, the mortality reduction being from 53% to 21% (a 63% reduction) at 3 
years in these patients.  This latter observation is consistent with prior demonstration of QRS 
prolongation on the surface ECG as being particularly potent, simple marker for the probability 
of all cause mortality and sudden death.
Present Status of Prophylactic ICDs
The evidence indicating that implanted defibrillators prolong life in patients who are susceptible 
to sudden cardiac death is compelling.   It is important to underline that the trials pertain 
exclusively to patients with coronary disease (as opposed to those with dilated or other forms of 
cardiomyopathy), and probably are not applicable to patients immediately after bypass surgery.  
No study has shown superiority of ICDs over medical therapy in patients with dilated 
cardiomyopathy, and a large study of ICDs vs. amiodarone (SCD-HeFT) will address this 
question.   With   these   exceptions,   such   patients   with   very   poor   ventricular   function 
unquestionably benefit from the implantation of a defibrillator, even if they are receiving 
optimal medical therapy.   Although the MADIT and MUSTT trials did not systematically 
compare the ICD to "best" medical therapy (almost certainly amiodarone), the absence of clear 
proof that amiodarone is effective, and the toxicity burden from amiodarone (which itself 
increases progressively over time), suggests that for the moment the defibrillator should be 
considered  clearly  superior   to  amiodarone  therapy  or   no  antiarrhythmic   therapy   in   the 
prevention   of   sudden   and   all   cause   mortality   in   susceptible   populations.   Importantly, 
defibrillators   in  the   MADIT  study  and  other   studies   were  implanted  with  virtually  no 
perioperative mortality, and a 2.5% incidence of non-fatal adverse events requiring surgical 
interventions (lead problems or infection).17   The main barrier to more widespread use of 
prophylactic implanted defibrillators, at least in the Indian context; though it applies as well to 
the west particularly in countries with government funded health care system, seems to be 
resource limitations, both with respect to device and implantation costs, and the availability of 
medical personnel to perform the procedures and follow the patients.   In addition, the total 
number of years added to life, as well as the quality of these added years, is not fully elucidated 
given the relatively short follow-up time of all of the studies published thus far.
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Who is The Appropriate Candidate?
For the time being, it seems appropriate to at least  consider  a prophylactic implanted 
defibrillator in all patients with a history of remote myocardial infarction and ejection fraction of 
<30%, provided they are receiving or have been considered for evidence based pharmacological 
therapies  including beta-blockers,  ACE inhibitors,  aspirin, statins,  and  spironolactone as 
indicated.  If revascularization is indicated and feasible, it should be performed.  The presence of 
nonsustained ventricular tachycardia on in-hospital or Holter monitoring probably adds some 
prognostic significance, although the amount of information contained in this finding is not 
clear.  Performing an electrophysiologic study for risk stratification is probably not required for 
most such patients.  The expectation of treatment benefit is amplified in patients with bundle 
branch block or QRS >120 msec.  
Following these considerations, it is appropriate and should be considered advisable to at least 
inform the patient of the treatment options available, unless there are severe co-morbidities, 
which reduce the expectation of treatment benefit.                                                           
References
1. Hauer RN, Aliot E, Block M, Capucci A, Luderitz B, Santini M, Vardas PE. Indications for 
implantable cardioverter defibrillator (ICD) therapy. Study Group on Guidelines on ICDs of the 
Working Group on Arrhythmias and the Working Group on Cardiac Pacing of the European 
Society of Cardiology. Eur Heart J. 2001;22:1074-81.                                                       
2.   Julian DG, Camm AJ, Frangin G, et al. Randomized trial of effect of amiodarone on 
mortality in patients with left ventricular dysfunction after recent myocardial infarction: 
EMIAT. Lancet 1997; 349:667-74.                                                                                       
3. Deedwania PC, Singh BN, Ellenbogen K, et al. Spontaneous conversion and maintenance of 
sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation. Circulation 
1998;   98:2574-2579.                                                                
4. Cairns JA, Connolly SJ, Roberts R, et al. Randomized trial of outcome after myocardial 
infarction   in   patients   with   frequent   or   repetitive   ventricular   premature   depolarizations: 
CAMIAT.   Lancet   1997;   349:675-82.                                                                
5.  Kober L, Bloch Thomsen PE, Moller M, et al. Danish Investigators of Arrhythmia and 
Mortality on Dofetilide (DIAMOND) Study Group. Effect of dofetilide in patients with recent 
myocardial   infarction  and   left-ventricular   dysfunction:  a   randomized  trial.   Lancet   2000; 
356:2052-8.
6. Moller M, Torp-Pedersen CT, Kober L. Dofetilide in patients with congestive heart failure 
and left ventricular dysfunction: safety aspects and effect on atrial fibrillation. The Danish 
Investigators of Arrhythmia and Mortality on Dofetilide (DIAMOND) Study Group. Congest 
Heart   Fail.   2001;7:146-150.                                                      
7.  Camm AJ, Pratt CM, Schwartz PJ, Al-Khalidi HR, Spyt M, Holroyde MJ, Karam R, 
Sonnenblick EH, Brum JM. Azimilide Post Infarct Survival Evaluation (ALIVE): Azimilide 
does not affect mortality in post-myocardial infarct patients. (abst) Circulation 2001;104:1B.
8.  The Antiarrhythmics Vs Implantable Defibrillator (AVID) Investigators. A comparison of 
Indian Pacing and Electrophysiology Journal (ISSN 0972-6292), 3(2): 60-66 (2003)Indranill Basu Ray, “Preventing Sudden Death And The Use Of Prophylactic           66 
Implanted Defibrillators”
antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near-
fatal ventricular arrhythmias. N Engl J Med 1997; 337:1576-83.
9.  Connolly SJ, Gent M, Roberts RS, et al. Canadian Implantable Defibrillator Study (CIDS): a 
randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 
2000; 101:1297-302.
10.  Kuck KH, Cappato R, Siebels J, Rüppel. Randomized comparison of antiarrhythmic drug 
therapy with implantable defibrillators in patients resuscitated from cardiac arrest : the Cardiac 
Arrest Study Hamburg (CASH). Circulation. 2000;102:748-54.
11.  Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck KH, Zipes DP, Greene HL, 
Boczor S, Domanski M, Follman D, Gent M, Roberts RS. Meta-analysis of the implantable 
cardioverter   defibrillator   secondary   prevention   trials.   AVID,   CASH   and   CIDS   studies. 
Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian 
Implantable Defibrillator Study. Eur Heart J. 2000;21:2071-8.
12.  Sheldon R, O'Brien BJ, Blackhouse G, Goeree R, Mitchell B, Klein G, Roberts RS, Gent M, 
Connolly SJ. Effect of clinical risk stratification on cost-effectiveness of the implantable 
cardioverter-defibrillator:   the   Canadian   implantable   defibrillator   study.   Circulation. 
2001;104:1622-6.
13.  Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, Levine JH, Saksena S, 
Waldo AL, Wilber D, Brown MW, Heo M. Improved survival with an implanted defibrillator in 
patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic 
Defibrillator Implantation Trial Investigators. N Engl J Med. 1996;335:1933-40.
14.  Bigger JT. Prophylactic use of implanted cardiac defibrillators in patients at high risk for 
ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass 
Graft (CABG) Patch Trial Investigators. N Engl J Med. 1997;337:1569-75.                          
15. Buxton, AE, et al., A randomized study of the prevention of sudden death in patients with 
coronary artery disease. Multicenter UnSustained Tachycardia Trial Investigators. N Engl J 
Med,   1999;341:1882-90.                                                                    
16.   Gregoratos, G et al ACC/AHA/NASPE 2002 Guideline for Implantation of Cardiac 
Pacemakers   and   Antiarrhythmia   Devices.   Available   at 
http://www.acc.org/clinical/guidelines/pacemaker/pacemaker.pdf.  
17. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, 
Brown MW, Andrews ML. Prophylactic implantation of a defibrillator in patients with 
myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877-83.
Indian Pacing and Electrophysiology Journal (ISSN 0972-6292), 3(2): 60-66 (2003)